RBTQ Stock Chart & Stats
€2.04
-€0.08(-4.42%)
At close: 4:00 PM EST
€2.04
-€0.08(-4.42%)
Day’s Range― - ―
52-Week Range€1.13 - €2.56
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€59.29M
Enterprise Value€51.17M
Total Cash (Recent Filing)€10.00M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 07, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,633,223
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.43Price Target Upside803.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage / Equity CushionEdesa’s near-zero debt and roughly $12.4M of equity materially reduce solvency risk and preserve strategic optionality. For a clinical-stage biotech this conservatism supports continued R&D spend, partnership negotiations and trial execution without immediate creditor pressure over the next several months.
Insider-led PIPE Financing Provides Near-term CapitalThe insider-led ~$3.5M PIPE directly extends runway to advance vitiligo and ARDS programs and signals management and sector-investor alignment. Durable impact: it enables planned development activities and regulatory preparation over the coming months, lowering near-term financing urgency.
Supportive Exploratory Clinical Signal For Lead AssetExploratory evidence that paridiprubart improved mortality and kidney outcomes validates the TLR4 target and could expand indication scope to multi-organ dysfunction. Structurally, such mechanistic signals improve program de-risking, inform trial design, and increase potential licensing or partnership value if confirmed.
Bears Say
Minimal Revenue; Large Net LossesEdesa generates virtually no commercial revenue while incurring multi-million dollar losses, meaning the business remains wholly development-stage. Over time this reliance on future trial success concentrates execution risk and could erode equity if clinical setbacks force additional financings.
Sustained Negative Operating And Free Cash FlowPersistent cash burn (~-$7.6M operating) constrains R&D pacing and increases dependency on external capital. Structurally, this elevates dilution and execution risk: repeated funding rounds may be required to complete pivotal studies or expand programs absent near-term revenue or big partnerships.
Expanded Equity Plan Increases Dilution CapacityApproving 750k extra shares and removing per-participant limits materially raises potential future dilution from stock comp or grants. Coupled with management's shift to RSU-heavy pay, this structurally increases share issuance risk and can dilute existing holders and EPS over time as financing and compensation rely on equity.
Edesa Biotech News
RBTQ FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was €1.13 and its highest was €2.56 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is €59.29M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 24 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -€0.43 earnings per share for the quarter, missing the consensus estimate of -€0.228 by -€0.202.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.38.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 9,633,223 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -€0.43 in its last earnings report, missing expectations of -€0.228. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in DE:RBTQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.43 (803.26% Upside)
€18.43 (803.26% Upside)
Blogger Sentiment
Bullish
DE:RBTQ Sentiment 70%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
238.64%
12-Months-Change
Fundamentals
Return on Equity
-82.34%
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
RBTQ Stock 12 Month Forecast
Average Price Target
€18.43
▲(803.26% Upside)
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Options Prices
Currently, No data available
---